There's a new leader at a long-time clinical research organization in the area.
Allendale-based QST Consultations said last week it hired Phil Doren for its CEO role.
John Quiring, who founded the company and has been acting as interim CEO since January, will continue as chief science officer and chairman of the board.
Doren joins the company with more than 25 years in the clinical research industry.
Most recently, he was the president of Secaucus, New Jersey-based Frontage Clinical Services, where he led early phase clinical research and pharmacometrics.
Previously, Doren was general manager and VP of clinical operations at Everest Clinical Research, global VP of biometrics at SynteractHCR, VP of clinical data analysis and reporting organization at Covance and VP and head of biostatistics for North America at Quintiles.
He has also held executive positions at eRT, TKL Research and Kendle.
He holds a B.S. from the University of Minnesota, as well as an M.S. and a doctorate from Texas A&M University.
“As a mature organization committed to high quality in clinical research, I look forward to enhancing the existing culture and business structure as we continue to diversify our therapeutic expertise and build on our current service offerings,” Doren said.
QST Consultations, founded in 1974, provides specialized clinical research support to the pharmaceutical and medical device industries.
The company specializes in clinical study design, protocol development, clinical operations, data management, biostatistical analysis, report writing and FDA consultation.